Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 201–300 of 1,020
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S., Lin, K. K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 174
Self-citationMenghi, F., Barthel, F. P., Yadav, V., Tang, M., Ji, B., Tang, Z., Carter, G. W., Ruan, Y., Scully, R., Verhaak, R. G. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.008 · Cited by 174
“WGS-based somatic structural variation calls from 13 other studies (Bailey et al., 2016; Bass et al., 2011; Berger et al., 2011; Campbell et al., 2010; Desmedt et al., 2015; Kataoka et al., 2015; Nik-Zainal et al., 2012, 2016; Northcott et al., 2012; Patch et al., 2015; Pinto et al., 2015; Stephens et al., 2009) were…”
MethodExploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Bailey, P., Chang, D. K., Forget, M.-A., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., Chattopadhyay, C., Kim, S.-H., Ekmekcioglu, S., Grimm, E. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35848 · Cited by 170
Self-citationSolimena, M., Schulte, A. M., Marselli, L., Ehehalt, F., Richter, D., Kleeberg, M., Mziaut, H., Knoch, K.-P., Parnis, J., Bugliani, M., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4500-3 · Cited by 170
“Comparing differentially expressed genes with pancreatic cancer transcriptomic signatures (see ESM Results) we found no evidence for contamination of PPP samples with cancer cells [28].”
BackgroundSelf-citationReprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion
Deborde, S., Gusain, L., Powers, A., Marcadis, A., Yu, Y., Chen, C.-H., Frants, A., Kao, E., Tang, L. H., Vakiani, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1690 · Cited by 162
Kinkead, H. L., Hopkins, A., Lutz, E., Wu, A. A., Yarchoan, M., Cruz, K., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 166
“All mutated epitopes predicted to bind to either H-2Kb or H-2Db with an affinity of ≤1,000 nM were manually curated by Integrated Genomics Viewer (39, 40).”
MethodMarchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M., Haider, S. M., Morton, J. P., Marsico, G., Vo, T., Laughlin-Toth, S., Ahmed, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01781 · Cited by 166
Self-citationStrategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 165
“Genomic analyses show that PDAC frequently upregulates multiple pathways involved in acquired immune suppression, and upregulation of these pathways is associated with poor survival (16).”
BackgroundA Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma
Lytle, N. K., Ferguson, L. P., Rajbhandari, N., Gilroy, K., Fox, R. G., Deshpande, A., Schürch, C. M., Hamilton, M., Robertson, N., Lin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.010 · Cited by 162
Yu, J., Sadakari, Y., Shindo, K., Suenaga, M., Brant, A., Almario, J. A. N., Borges, M., Barkley, T., Fesharakizadeh, S., Ford, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311166 · Cited by 164
Self-citationAltered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Escobar-Hoyos, L. F., Penson, A., Kannan, R., Cho, H., Pan, C.-H., Singh, R. K., Apken, L. H., Hobbs, G. A., Luo, R., Lecomte, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.010 · Cited by 162
“Approximately 40% of PDACs have hotspot missense TP53mutations, while 30% have truncating mutations (Bailey et al., 2016; Collisson et al., 2011; Moffitt et al., 2015).”
BackgroundMethodInfluentialSelf-citationTargeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Dreyer, S. B., Upstill-Goddard, R., Paulus-Hock, V., Paris, C., Lampraki, E.-M., Dray, E., Serrels, B., Caligiuri, G., Rebus, S., Plenker, D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.043 · Cited by 163
Self-citationPancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K., Bailey, P., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 162
Self-citationGozdecka, M., Meduri, E., Mazan, M., Tzelepis, K., Dudek, M., Knights, A. J., Pardo, M., Yu, L., Choudhary, J. S., Metzakopian, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0114-z · Cited by 162
Wigger, L., Barovic, M., Brunner, A.-D., Marzetta, F., Schöniger, E., Mehl, F., Kipke, N., Friedland, D., Burdet, F., Kessler, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00420-9 · Cited by 161
Deng, Y., Xia, X., Zhao, Y., Zhao, Z., Martinez, C., Yin, W., Yao, J., Hang, Q., Wu, W., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27349-7 · Cited by 157
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
“485 Additionally, we propose that SMAD4 status, which is a frequent deletion event in PDAC (2), 486 should be assessed as patient inclusion criteria for clinical trials testing KRAS* inhibitors.”
BackgroundMethodTargeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
Orozco, C. A., Martinez-Bosch, N., Guerrero, P. E., Vinaixa, J., Dalotto-Moreno, T., Iglesias, M., Moreno, M., Djurec, M., Poirier, F., Gabius, H.-J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722434115 · Cited by 158
“Notwithstanding, recent genome-wide studies have identified molecular signatures (83) and unique neoantigen properties (84) that may be useful for stratifying PDA patients for immunotherapy.”
BackgroundGemenetzis, G., Groot, V. P., Yu, J., Ding, D., Teinor, J. A., Javed, A. A., Wood, L. D., Burkhart, R. A., Cameron, J. L., Makary, M. A., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002925 · Cited by 159
Self-citationDrugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Cevik, N. C., Arik Sever, E., Unutmaz, D., Ceyhan, G. O., Demir, I. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 155
“The authors found that the chromatin regions expressing the cytokine transcription factors, inhibitory receptors, effector marker proteinIL-10, IFN-γ, and TNF-α, NR4a2, NFAT pathway were more accessible and transcriptional accessibility differentially changed in CD8+ based on TIM3 expression in the course of chronic i…”
BackgroundMechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
“N Engl J Med 2018;378(2):113–25 doi 10.”
InfluentialJones, M. R., Williamson, L. M., Topham, J. T., Lee, M. K. C., Goytain, A., Ho, J., Denroche, R. E., Jang, G., Pleasance, E., Shen, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0191 · Cited by 156
“Molecular subtyping Molecular subtyping was performed based on gene-expression signatures detailed in Moffitt and colleagues (18), Bailey and colleagues (19), and Collisson and colleagues (20).”
MethodSelf-citationZhang, Y., Zoltan, M., Riquelme, E., Xu, H., Sahin, I., Castro-Pando, S., Montiel, M. F., Chang, K., Jiang, Z., Ling, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.041 · Cited by 155
Self-citationDDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis
Deng, J., Kang, Y., Cheng, C.-C., Li, X., Dai, B., Katz, M. H., Men, T., Kim, M. P., Koay, E. A., Huang, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146133 · Cited by 154
“Constitutive KRAS and NF-B activation are signature alterations in PDAC (49).”
BackgroundMolecular subtyping of cancer: current status and moving toward clinical applications
Zhao, L., Lee, V. H. F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby026 · Cited by 151
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Storz, P., & Crawford, H. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.059 · Cited by 154
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
Davies, A., Zoubeidi, A., Beltran, H., & Selth, L. A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0225 · Cited by 182
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.062 · Cited by 150
Self-citationJuiz, N., Elkaoutari, A., Bigonnet, M., Gayet, O., Roques, J., Nicolle, R., Iovanna, J., & Dusetti, N. (2020) · The FASEB Journal · doi:10.1096/fj.202000363rr · Cited by 147
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers
Zheng, C., Fass, J. N., Shih, Y.-P., Gunderson, A. J., Sanjuan Silva, N., Huang, H., Bernard, B. M., Rajamanickam, V., Slagel, J., Bifulco, C. B., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.005 · Cited by 149
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Carpenter, E. S., Elhossiny, A. M., Kadiyala, P., Li, J., McGue, J. J., Griffith, B. D., Zhang, Y., Edwards, J., Nelson, S., Lima, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0013 · Cited by 171
MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147
“2012; Guinney et al., 2015) and include frequent oncogenic mutations in KRAS , BRAF and TP53 , which are also common in other cancer types, such as melanoma (Krauthammer et al., 2012), and malignancies of the lung (Cancer Genome Atlas Research Network, 2014) and pancreas (Bailey et al., 2016).”
Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells
Jagušt, P., de Luxán‐Delgado, B., Parejo-Alonso, B., & Sancho, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00203 · Cited by 154
Guo, W., Zhang, Y., Guo, S., Mei, Z., Liao, H., Dong, H., Wu, K., Ye, H., Zhang, Y., Zhu, Y., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02557-5 · Cited by 145
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2605555 · Cited by 147
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
IPMNs with co-occurring invasive cancers: neighbours but not always relatives
Felsenstein, M., Noë, M., Masica, D. L., Hosoda, W., Chianchiano, P., Fischer, C. G., Lionheart, G., Brosens, L. A. A., Pea, A., Yu, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315062 · Cited by 145
Self-citationXue, M., Zhu, Y., Jiang, Y., Han, L., Shi, M., Su, R. J., Wang, L., Xiong, C., Wang, C., Wang, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40314-w · Cited by 165
“Consistent with previous studies, the basal-like signature was an unfavorable prognostic factor in TCGA-PAAD cohort 38,40,41 (Fig.”
Tiwari, A., Tashiro, K., Dixit, A., Soni, A., Vogel, K., Hall, B., Shafqat, I., Slaughter, J., Param, N., Le, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.046 · Cited by 142
Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., Golan, T., Braconi, C., Froeling, F. E. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03238 · Cited by 158
“20 21-29 This uncertainty is primarily because of inconsistencies in HRD measurement and de fi nitions (gene-level tests, genomic scars, signatures, or a combination of these methods); and the dif-fi culties in assessing the contribution of each genomic event.”
Self-citationMarteil, G., Guerrero, A., Vieira, A. F., de Almeida, B. P., Machado, P., Mendonça, S., Mesquita, M., Villarreal, B., Fonseca, I., Francia, M. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03641-x · Cited by 145
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 140
Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
Lee, A. Y. L., Dubois, C. L., Sarai, K., Zarei, S., Schaeffer, D. F., Sander, M., & Kopp, J. L. (2019) · Gut · doi:10.1136/gutjnl-2017-314426 · Cited by 139
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
Jiang, H., Torphy, R. J., Steiger, K., Hongo, H., Ritchie, A. J., Kriegsmann, M., Horst, D., Umetsu, S. E., Joseph, N. M., McGregor, K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136760 · Cited by 127
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 148
Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids
Fujii, M., Clevers, H., & Sato, T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.048 · Cited by 140
Farrell, A. S., Joly, M. M., Allen-Petersen, B. L., Worth, P. J., Lanciault, C., Sauer, D., Link, J., Pelz, C., Heiser, L. M., Morton, J. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01967-6 · Cited by 138
Self-citationFoucher, E. D., Ghigo, C., Chouaib, S., Galon, J., Iovanna, J., & Olive, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01044 · Cited by 138
“Indeed, several genetic and transcriptomic studies have demonstrated the classification of PDAC into two or more subtypes including basal versus classic or immunogenic versus non-immunogenic (72).”
BackgroundEpigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Heßmann, E., Johnsen, S. A., Siveke, J. T., & Ellenrieder, V. (2016) · Gut · doi:10.1136/gutjnl-2016-312539 · Cited by 148
Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets
Whittle, M. C., & Hingorani, S. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.044 · Cited by 137
ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity
Alcalá, S., Sancho, P., Martinelli, P., Navarro, D., Pedrero, C., Martín-Hijano, L., Valle, S., Earl, J., Rodríguez‐Serrano, M., Ruíz-Cañas, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16395-2 · Cited by 142
The biological underpinnings of therapeutic resistance in pancreatic cancer
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 159
“Recent studies using bulk RNA sequencing have proposed multiple gene expression classifications of PDAC (Collisson et al. 2011; Moffitt et al. 2015; Bailey et al. 2016; The Cancer Genome Atlas Research Network 2017; Puleo et al. 2018; Chan-Seng-Yue et al. 2020).”
BackgroundInfluentialThe microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 144
“alterations, which is influenced by host immunity, diet, and environmental and microbial exposures [1-7].”
BackgroundN Kalimuthu, S., Wilson, G. W., Grant, R. C., Seto, M., O’Kane, G., Vajpeyi, R., Notta, F., Gallinger, S., & Chetty, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318217 · Cited by 132
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
Chiaravalli, M., Reni, M., & O'Reilly, E. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.007 · Cited by 154
Park, Y., Chui, M. H., Suryo Rahmanto, Y., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 132
Sharbeen, G., McCarroll, J. A., Akerman, A., Kopecky, C., Youkhana, J., Kokkinos, J., Holst, J., Boyer, C. A., Erkan, M., Goldstein, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2496 · Cited by 145
“Similar results were obtained when we analysed the ICGC publicly 160 available mRNA data (26) (Figure S2).”
ResultSelf-citationTGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Ottaviani, S., Stebbing, J., Frampton, A. E., Zagorac, S., Krell, J., de Giorgio, A., Trabulo, S. M. D., Nguyen, V. T. M., Magnani, L., Feng, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03962-x · Cited by 139
“After mapping of the sequencing reads followed by gene expression analysis (4) the transcripts are then sorted from the most enriched to the least enriched in AGO2 for AGO2-RIP-seq, as well as from the least down-regulated to most up-regulated for RNA-seq.”
Emerging roles of spliceosome in cancer and immunity
Yang, H., Beutler, B., & Zhang, D. (2021) · Protein & Cell · doi:10.1007/s13238-021-00856-5 · Cited by 149
“2014), pancreatic ductal adenocarcinomas (Bailey et al. 2016), and non-small cell lung adenocarcinomas (Imielinski et al.”
BackgroundInfluentialChemotherapy and radiotherapy for advanced pancreatic cancer
Chin, V. T., Nagrial, A. M., Sjoquist, K. M., O'Connor, C. A., Chantrill, L. A., Biankin, A. V., Scholten, R. J. P. M., & Yip, D. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011044.pub2 · Cited by 167
Self-citationKhaliq, A. M., Rajamohan, M., Saeed, O. A. M., Mansouri, K., Adil, A., Zhang, C., Turk, A. A., Carstens, J. L., House, M. G., Hayat, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01914-4 · Cited by 161
“The sequencing data were mapped to the human reference genome (GRCh38) using the Space Ranger count module, with GENCODE v.32 serving as the gene annotation reference (Supplementary Table 6).”
InfluentialMolecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 153
The BRG1 ATPase of Human SWI/SNF Chromatin Remodeling Enzymes as a Driver of Cancer
Wu, Q., Lian, J. B., Stein, J. L., Stein, G. S., Nickerson, J. A., & Imbalzano, A. N. (2017) · Epigenomics · doi:10.2217/epi-2017-0034 · Cited by 143
The role of gut microbiota in T cell immunity and immune mediated disorders
Shim, J. A., Ryu, J. H., Jo, Y., & Hong, C. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79430 · Cited by 155
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
Amisaki, M., Zebboudj, A., Yano, H., Zhang, S. L., Payne, G., Chandra, A. K., Yu, R., Guasp, P., Sethna, Z. M., Ohmoto, A., et al. (2025) · Nature · doi:10.1038/s41586-024-08426-5 · Cited by 154
“For the ICGC cohort, RNA-seq data were obtained from previously published data 64 .”
Porter, R. L., Magnus, N. K. C., Thapar, V., Morris, R., Szabolcs, A., Neyaz, A., Kulkarni, A. S., Tai, E., Chougule, A., Hillis, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914915116 · Cited by 129
“Comparison with QM subtype frequency in resected PDAC tumors as determined by RNA expression analysis by others [Collisson 20/66, 30% (17); Moffitt QM, 36/125, 29% (3); Bailey 25/96, 26% 9 (1); see also ref.”
The dark side of tumor-associated endothelial cells
Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 144
“pancreatic ductal adenocarcinomas (PDACs) defined 4 PDAC subtypes which drive different evolution and clinical outcome [190].”
BackgroundChen, M., Gao, Q., Ning, H., Chen, K., Gao, Y., Yu, M., Liu, C., Zhou, W., Pan, J., Wei, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.020 · Cited by 176
Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128
Self-citationPrecancerous neoplastic cells can move through the pancreatic ductal system
Makohon-Moore, A. P., Matsukuma, K., Zhang, M., Reiter, J. G., Gerold, J. M., Jiao, Y., Sikkema, L., Attiyeh, M. A., Yachida, S., Sandone, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0481-8 · Cited by 120
Self-citationRath, N., Morton, J. P., Julian, L., Helbig, L., Kadir, S., McGhee, E. J., Anderson, K. I., Kalna, G., Mullin, M., Pinho, A. V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606743 · Cited by 127
Self-citationOrganoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L., Huang, L., Akshinthala, D., Perea, S., Gonzalez, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 121
“We further classified PDOs based on previously published PDAC subtype classifiers (6, 32, 33) using mRNA expression profiles.”
MethodDownstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio, I. M., Regi, P., Giardino, A., Scopelliti, F., Girelli, R., Bassi, C., Gobbo, S., Martini, P. T., Capelli, P., D’Onofrio, M., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5885-4 · Cited by 126
Self-citationKrieger, T. G., Blanc, S. L., Jabs, J., Ten, F. W., Ishaque, N., Jechow, K., Debnath, O., Leonhardt, C.-S., Giri, A., Eils, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26059-4 · Cited by 146
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 148
Patra, K. C., Bardeesy, N. M., & Mizukami, Y. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.3 · Cited by 134
“45 Multiple other recurrent mutations have been identified in PDA, most notably in chromatin regulators (e.g., ARID1A and KDM6A), 3,38 although the timing of such mutations and their roles in disease pathogenesis remain under study.”
BackgroundMoving towards a molecular taxonomy of autoimmune rheumatic diseases
Barturen, G., Beretta, L., Cervera, R., van Vollenhoven, R., & Alarcón-Riquelme, M. E. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.220 · Cited by 133
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels
Novo, D., Heath, N., Mitchell, L., Caligiuri, G., MacFarlane, A., Reijmer, D., Charlton, L., Knight, J., Calka, M., McGhee, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07339-y · Cited by 125
Self-citationMiyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 124
“Moreover, the oxidative phosphorylation and fatty acid metabolism pathways, which have been associated with the PDAC progenitor/classical subtypes (4,33), were upregulated in cancer cells from IGO tumors (Fig.”
BackgroundResultInfluentialSelf-citationPancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 150
“The squamous subtype is preferentially associated with TP53 and KDM6A mutations; high TP63 expression is a typical feature of the squamous subtype [19].”
BackgroundResultInfluentialHNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Brunton, H., Caligiuri, G., Cunningham, R., Upstill-Goddard, R., Bailey, U.-M., Garner, I. M., Nourse, C., Dreyer, S., Jones, M., Moran-Jones, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107625 · Cited by 124
Self-citationSato, M., Matsumoto, M., Saiki, Y., Alam, M., Nishizawa, H., Rokugo, M., Brydun, A., Yamada, S., Kaneko, M. K., Funayama, R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-4099 · Cited by 122
Defining the molecular pathology of pancreatic body and tail adenocarcinoma
Initiative, A. P. C. G., Dreyer, S. B., Jamieson, N. B., Upstill-Goddard, R., Bailey, P. J., McKay, C. J., Biankin, A. V., & Chang, D. K. (2018) · British Journal of Surgery · doi:10.1002/bjs.10772 · Cited by 122
Self-citationGlucose Metabolism in Pancreatic Cancer
Liang, Y., Raj, P. S., Yao, W., & Ying, H. (2019) · Cancers · doi:10.3390/cancers11101460 · Cited by 145
Espinet, E., Gu, Z., Imbusch, C. D., Giese, N. A., Büscher, M., Safavi, M., Weisenburger, S., Klein, C., Vogel, V., Falcone, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1202 · Cited by 122
“Normalized expression data, subtype annotation, tumor cellularity (QPURE) estimation, and survival data were obtained from the Supplementary Information accompanying the Bailey and colleagues publication (25).”
Self-citationImmune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 133
The landscape of multiscale transcriptomic networks and key regulators in Parkinson’s disease
Wang, Q., Zhang, Y., Wang, M., Song, W.-M., Shen, Q., McKenzie, A., Choi, I., Zhou, X., Pan, P.-Y., Yue, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13144-y · Cited by 121
The Evolutionary Origins of Recurrent Pancreatic Cancer
Sakamoto, H., Attiyeh, M. A., Gerold, J. M., Makohon-Moore, A. P., Hayashi, A., Hong, J., Kappagantula, R., Zhang, L., Melchor, J. P., Reiter, J. G., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1508 · Cited by 119
“8 9 10 Discussion 11 To date genomic studies of PDA have primarily relied on resections or biopsies of 12 treatment naïve disease (9,36,37).”
BackgroundSelf-citationEmerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 138
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 145
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer
Initiative, A. P. C. G., Harris, N. L. E., Vennin, C., Conway, J. R. W., Vine, K. L., Pinese, M., Cowley, M. J., Shearer, R. F., Lucas, M. C., Herrmann, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.63 · Cited by 119
Self-citationHuman Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors
Romero-Calvo, I., Weber, C. R., Ray, M., Brown, M., Kirby, K., Nandi, R. K., Long, T. M., Sparrow, S. M., Ugolkov, A., Qiang, W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0531 · Cited by 119
Cell of origin influences pancreatic cancer subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118
“We used publicly available gene expression and clinical data for the ICGC Australian (13), ICGC Canadian (PACA-CA, downloaded from the ICGC data portal – https://dcc.”
BackgroundMethodResultInfluentialPitt, J. J., Riester, M., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Oluwasola, O., Veloso, A., Labrot, E., Wang, S., Odetunde, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06616-0 · Cited by 161
Seppälä, T. T., Zimmerman, J. W., Sereni, E., Plenker, D., Suri, R., Rozich, N., Blair, A., Thomas, D. L., Teinor, J., Javed, A., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004200 · Cited by 117
Self-citationBlood biomarkers for differential diagnosis and early detection of pancreatic cancer
Al-Shaheri, F. N., Alhamdani, M. S. S., Bauer, A. S., Giese, N. A., Büchler, M. W., Hackert, T., & Hoheisel, J. D. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102193 · Cited by 132
Chou, A., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A., Stark, R., Drury, A., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315144 · Cited by 117
Self-citationWan, Y., Xu, L., Liu, Z., Yang, M., Jiang, X. J., Zhang, Q., & Huang, J. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2580-y · Cited by 145
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.